|
Mar 29
|
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
|
|
Mar 7
|
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
|
|
Mar 6
|
Insider Sells Shares of Editas Medicine Inc (EDIT)
|
|
Mar 4
|
1 Beaten-Down Stock With 55% Upside, According to Wall Street
|
|
Feb 10
|
Top 11 CRISPR Stocks To Invest In
|
|
Feb 6
|
What Makes Editas (EDIT) a New Buy Stock
|
|
Jan 31
|
Editas Medicine to Participate in Upcoming Investor Conferences
|
|
Jan 28
|
2 Under-the-Radar Stocks With Incredible Upside Potential
|
|
Jan 25
|
Editas Medicine (NASDAQ:EDIT) shareholders have endured a 87% loss from investing in the stock three years ago
|
|
Jan 15
|
Down 88%, Could Editas Medicine Be a Good Investment Now?
|
|
Dec 23
|
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
|
|
Dec 10
|
12 Best Genomics Stocks To Buy Now
|
|
Dec 5
|
1 Promising Stock Down 66% That Could Skyrocket in 2024
|
|
Nov 29
|
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
|
|
Nov 27
|
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 69%
|
|
Aug 30
|
Editas Medicine Announces Upcoming Investor Events
|
|
Aug 28
|
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
|
|
Jun 29
|
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
|
|
Jun 28
|
Is Editas Medicine Stock a Buy Now?
|
|
May 1
|
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
|